As MIRA proceeds towards an acquisition that will open up New markets for the company, the acquired molecule moves into focus

MIRA’s proposed acquisition of SKNY Pharmaceuticals (SKNY), currently in progress and expected to close during Q3 2025, would add to MIRA’s development pipeline SKNY-1, a preclinical-stage oral drug candidate for weight loss and smoking cessation. SKNY-1 would become MIRA’s second development priority, following its lead product candidate, Ketamir-2, into clinical development in 2026.